KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBIT (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBIT readings, the most recent being $260.4 million for Q4 2025.

  • On a quarterly basis, EBIT rose 5876.06% to $260.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $341.0 million, a 13508.93% increase, with the full-year FY2025 number at $341.0 million, up 13508.93% from a year prior.
  • EBIT hit $260.4 million in Q4 2025 for Biocryst Pharmaceuticals, up from $29.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $260.4 million in Q4 2025 to a low of -$52.2 million in Q4 2021.
  • Median EBIT over the past 5 years was -$19.1 million (2022), compared with a mean of -$4.6 million.
  • Biggest five-year swings in EBIT: decreased 25.38% in 2021 and later skyrocketed 5876.06% in 2025.
  • Biocryst Pharmaceuticals' EBIT stood at -$52.2 million in 2021, then rose by 11.24% to -$46.3 million in 2022, then grew by 7.86% to -$42.7 million in 2023, then soared by 89.44% to -$4.5 million in 2024, then skyrocketed by 5876.06% to $260.4 million in 2025.
  • The last three reported values for EBIT were $260.4 million (Q4 2025), $29.6 million (Q3 2025), and $29.8 million (Q2 2025) per Business Quant data.